$120 Million is the total value of NEXTHERA CAPITAL LP's 23 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 95.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ICPT | Buy | Intercept Pharmaceuticals Inc | $12,130,000 | +807.3% | 152,441 | +1175.4% | 10.10% | +522.5% |
| INSM | Buy | Insmed Inc | $12,051,000 | +45.8% | 470,741 | +65.6% | 10.04% | +0.1% |
| BOLD | Buy | Audentes Therapeutics Inc | $11,131,000 | +13.8% | 294,013 | +17.3% | 9.27% | -21.9% |
| NBIX | Buy | Neurocrine Biosciences Inc | $7,800,000 | +268.3% | 92,380 | +284.3% | 6.50% | +152.8% |
| SRPT | Buy | Sarepta Therapeutics Inc | $7,646,000 | +201.6% | 50,317 | +136.6% | 6.37% | +107.0% |
| GBT | Buy | Global Blood Therapeutics Inc | $7,485,000 | +62.4% | 142,305 | +63.4% | 6.23% | +11.4% |
| IMMU | Buy | Immunomedics Inc | $7,270,000 | +13.1% | 524,140 | +56.6% | 6.06% | -22.4% |
| CHRS | New | Coherus Biosciences Inc | $6,991,000 | – | 316,316 | +100.0% | 5.82% | – |
| ASND | New | Ascendis Pharma A/Ssponsored adr | $6,940,000 | – | 60,266 | +100.0% | 5.78% | – |
| PCRX | New | Pacira BioSciences Inc | $6,484,000 | – | 149,086 | +100.0% | 5.40% | – |
| URGN | Buy | UroGen Pharma Ltd | $6,357,000 | +29.8% | 176,866 | +33.4% | 5.30% | -10.9% |
| QURE | Buy | uniQure NV | $4,680,000 | +102.2% | 59,883 | +54.3% | 3.90% | +38.8% |
| AMRN | Buy | Amarin Corp PLCspons adr new | $4,465,000 | +44.6% | 230,295 | +54.9% | 3.72% | -0.7% |
| ABBV | New | AbbVie Inc | $3,831,000 | – | 52,681 | +100.0% | 3.19% | – |
| BHVN | New | Biohaven Pharmaceutical Holdin | $3,773,000 | – | 86,165 | +100.0% | 3.14% | – |
| MYL | New | Mylan NV | $1,953,000 | – | 102,560 | +100.0% | 1.63% | – |
| ITCI | New | Intra-Cellular Therapies Inc | $1,865,000 | – | 143,665 | +100.0% | 1.55% | – |
| REGN | New | Regeneron Pharmaceuticals Inc | $1,774,000 | – | 5,668 | +100.0% | 1.48% | – |
| MDGL | Buy | Madrigal Pharmaceuticals Inc | $1,616,000 | +274.1% | 15,423 | +346.8% | 1.35% | +156.9% |
| DERM | New | Dermira Inc | $1,320,000 | – | 138,102 | +100.0% | 1.10% | – |
| GILD | New | Gilead Sciences Inc | $1,263,000 | – | 18,697 | +100.0% | 1.05% | – |
| ANAB | New | AnaptysBio Inc | $679,000 | – | 12,026 | +100.0% | 0.57% | – |
| AGN | Sell | Allergan PLC | $560,000 | -72.1% | 3,347 | -75.6% | 0.47% | -80.9% |
| BMRN | Exit | BioMarin Pharmaceutical Inc | $0 | – | -8,250 | -100.0% | -0.89% | – |
| SAGE | Exit | Sage Therapeutics Inc | $0 | – | -6,200 | -100.0% | -1.20% | – |
| DCPH | Exit | Deciphera Pharmaceuticals Inc | $0 | – | -42,865 | -100.0% | -1.21% | – |
| CHMA | Exit | Chiasma Inc | $0 | – | -203,948 | -100.0% | -1.29% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals Ltd | $0 | – | -67,692 | -100.0% | -1.48% | – |
| ACOR | Exit | Acorda Therapeutics Inc | $0 | – | -154,806 | -100.0% | -2.50% | – |
| EXEL | Exit | Exelixis Inc | $0 | – | -90,356 | -100.0% | -2.61% | – |
| CBAY | Exit | Cymabay Therapeutics Inc | $0 | – | -210,257 | -100.0% | -3.39% | – |
| NVS | Exit | Novartis AGsponsored adr | $0 | – | -45,329 | -100.0% | -4.65% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -325,526 | -100.0% | -5.08% | – |
| BHC | Exit | Bausch Health Cos Inc | $0 | – | -205,660 | -100.0% | -6.16% | – |
| HRTX | Exit | Heron Therapeutics Inc | $0 | – | -388,623 | -100.0% | -11.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.